Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 148
mi
from
Reno, NV
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 148
mi
from
Reno, NV
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1369
mi
from
Bronx, NY
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1369
mi
from
Bronx, NY
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 13544
mi
from
Greensboro, NC
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 13544
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Raleigh, NC
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Winston-Salem, NC
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10522
mi
from
Canton, OH
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10522
mi
from
Canton, OH
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Cincinnati, OH
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 11
mi
from
Cleveland, OH
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 11
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Columbus, OH
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Oklahoma City, OK
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10183
mi
from
Philadelphia, PA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10183
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 12467
mi
from
Mount Pleasant, SC
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 12467
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 13560
mi
from
Bristol, TN
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 13560
mi
from
Bristol, TN
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 084
mi
from
Memphis, TN
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 084
mi
from
Memphis, TN
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1310
mi
from
Nashville, TN
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1310
mi
from
Nashville, TN
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10372
mi
from
Arlington, TX
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10372
mi
from
Arlington, TX
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10405
mi
from
Austin, TX
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10405
mi
from
Austin, TX
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10729
mi
from
Mansfield, TX
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10729
mi
from
Mansfield, TX
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1343
mi
from
Salt Lake City, UT
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1343
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 12222
mi
from
Charlottesville, VA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 12222
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1339
mi
from
Roanoke, VA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1339
mi
from
Roanoke, VA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Southview Medical Group, P.C.
mi
from
Birmingham, AL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Southview Medical Group, P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Simon-Williamson Clinic, P.C.
mi
from
Birmingham, AL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Simon-Williamson Clinic, P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Achieve Clinical Research
mi
from
Birmingham, AL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
East Valley Family Physicians, PC
mi
from
Chandler, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
East Valley Family Physicians, PC
mi
from
Chandler, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research
mi
from
Chandler, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research
mi
from
Chandler, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Warner Family Practice
mi
from
Chandler, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Warner Family Practice
mi
from
Chandler, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Clinical Research Advantage/Fountain Hills Family Practice
mi
from
Fountain Hills, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Clinical Research Advantage/Fountain Hills Family Practice
mi
from
Fountain Hills, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Neurological Physicians of Arizona
mi
from
Gilbert, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Neurological Physicians of Arizona
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Thunderbird Internal Medicine
mi
from
Glendale, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Thunderbird Internal Medicine
mi
from
Glendale, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Lenzmeier Family Practice
mi
from
Glendale, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Lenzmeier Family Practice
mi
from
Glendale, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Central Arizona Medical Associates, PC
mi
from
Mesa, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Central Arizona Medical Associates, PC
mi
from
Mesa, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Desert Clinical Research
mi
from
Mesa, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Desert Clinical Research
mi
from
Mesa, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Family Practice Specialists, Ltd
mi
from
Phoenix, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Family Practice Specialists, Ltd
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Clinical Research Advantage Inc./Central Phoenix Medical Center LLC
mi
from
Phoenix, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Clinical Research Advantage Inc./Central Phoenix Medical Center LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Thunderbird Internal Medicine
mi
from
Phoenix, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Thunderbird Internal Medicine
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Tatum Highlands Medical Associates, PLLC
mi
from
Phoenix, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Tatum Highlands Medical Associates, PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research
mi
from
Scottsdale, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Fiel Family and Sports Medicine
mi
from
Tempe, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Fiel Family and Sports Medicine
mi
from
Tempe, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Arizona Community Physicians
mi
from
Tucson, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Arizona Community Physicians
mi
from
Tucson, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Orange Grove Family Practice
mi
from
Tucson, AZ
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Orange Grove Family Practice
mi
from
Tucson, AZ
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Cassidy Medical Group
mi
from
Carlsbad, CA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Cassidy Medical Group
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Allied Clinical Research
mi
from
Gold River, CA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Allied Clinical Research
mi
from
Gold River, CA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research
mi
from
Santa Rosa, CA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Cassidy Medical Group
mi
from
Vista, CA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Cassidy Medical Group
mi
from
Vista, CA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Mile High Primary Care
mi
from
Aurora, CO
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Mile High Primary Care
mi
from
Aurora, CO
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Alpine Clinical Research Center
mi
from
Boulder, CO
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Alpine Clinical Research Center
mi
from
Boulder, CO
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Clinical Research Advantage, Inc. / Colorado Springs Family Practice
mi
from
Colorado Springs, CO
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Clinical Research Advantage, Inc. / Colorado Springs Family Practice
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Comprehensive Clinical Development-Washington DC
mi
from
Washington,
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Comprehensive Clinical Development-Washington DC
mi
from
Washington,
Click here to add this to my saved trials